Consistent with the predicted results, significant differences were observed in the expression levels of the above-mentioned five FRGs (DPP4, MUC1, SCP2, SLC1A4, and TF.)between NAFLD patients and healthy subjects (Fig. 3a–e). The gene discussed is SCP2; the disease is metabolic dysfunction-associated steatotic liver disease.